Cellular Therapy · Comparison
Muse Cells vs MSCs vs iPSCs
A side-by-side reference for physicians choosing between Dezawa Muse cells, bulk mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs).
| Property | Muse cells | MSCs | iPSCs |
|---|---|---|---|
| Source | Endogenous, SSEA-3+ subset of MSCs | Bone marrow / adipose / cord | Reprogrammed somatic cells |
| Differentiation | All three germ layers (pluripotent-like) | Tri-lineage mesodermal | All three germ layers |
| Genetic reprogramming | None | None | Required (viral / episomal) |
| Tumorigenicity (preclinical) | Not observed | Not observed | Teratoma risk |
| Homing to injury | S1P-mediated, active | Limited | Requires engineering |
| Clinical readiness | Human trials, aesthetic use | Widely used | Mostly research |
Frequently asked questions
Are Muse cells a type of MSC?
Muse cells are a defined SSEA-3+ subpopulation found within MSC preparations, but they behave differently: they are pluripotent-like, home to injury via S1P signaling, and differentiate across all three germ layers. Bulk MSCs are tri-lineage limited.
Why aren't iPSCs used the way Muse cells are?
iPSCs require genetic reprogramming (typically viral factors) and carry teratoma risk in preclinical models. Muse cells are endogenous, non-reprogrammed, and non-tumorigenic in published studies — a very different risk profile for clinical use.
Which cell type is 'best' for a regenerative practice?
There is no single best cell — it depends on indication, regulation, and sourcing. Muse cells are attractive when you need pluripotent-like differentiation plus a safety profile suitable for autologous or allogeneic clinical work.
Keep reading
Deciding which platform fits your practice?
Watch the Summit faculty walk through real cases with Muse cells, MSCs, and exosomes — or request info about bringing Dezawa MuseCells and MuseExosomes into your clinic.